During the third quarter, we continued to experience a turbulent market, as our customers faced ongoing price pressure and trade-related challenges, leading to general uncertainty and hesitation. While navigating these complex market dynamics, we made solid progress with our Data Quality initiative as we secured key approvals allowing us to initiate patient recruitment. In parallel, we started our share buyback program, reflecting our confidence in the long-term development of ContextVision.
